GZGeng Zhang

Geng Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Geng Zhang has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Regional Disparities in the Uptake of Differentiated Influenza Vaccines

    by Salaheddin Mahmud, Gurpreet Pabla, Christiaan Righolt, Geng Zhang, Matthew Loiacono, Edward Thommes, Heidi Kabler, Ayman Chit

    Significant racial/ethnic inequities in the uptake of differentiated influenza vaccines (DIVs) have been previously reported, though less is known about regional disparities. We conducted a retrospective longitudinal study (2014/15-2017/18 influenza seasons) among privately insured adults aged 65+ years in the US. The exposure was beneficiary’s area of residence (US Census Bureau division) and outcome was type of influenza vaccine: differentiated (High-Dose [HDV], adjuvanted, recombinant, and cell-based) versus standard-dose egg-based. Among those vaccinated in physician offices, beneficiaries in the East North Central region were twice as likely to receive a DIV vs those in the South Atlantic, whereas those in the East and West South Central were least likely. Disparities became more pronounced in models adjusted for individual and community characteristics, suggesting that crude uptake estimates understate the true magnitude of disparities. Regional disparities remained even in fully adjusted models, pointing to currently poorly understood factors that may include quality of healthcare, client health literacy and engagement, and other political and cultural factors.

  • Open Access

    Supplementary Table 1, Figure 1 - 4 from FOXL1, a Novel Candidate Tumor Suppressor, Inhibits Tumor Aggressiveness and Predicts Outcome in Human Pancreatic Cancer

    by Geng Zhang, Peijun He, Jochen Gaedcke, B. Michael Ghadimi, Thomas Ried, Harris G. Yfantis, Dong H. Lee, Nader Hanna, H. Richard Alexander, S. Perwez Hussain

  • Open Access

    Supplementary Table 1, Figure 1 - 4 from FOXL1, a Novel Candidate Tumor Suppressor, Inhibits Tumor Aggressiveness and Predicts Outcome in Human Pancreatic Cancer

    by Geng Zhang, Peijun He, Jochen Gaedcke, B. Michael Ghadimi, Thomas Ried, Harris G. Yfantis, Dong H. Lee, Nader Hanna, H. Richard Alexander, S. Perwez Hussain

    PDF file - 612K, Table S1. Characteristics of patient population. Figure S1. An inverse association between FOXL1 and ZEB1 expressions in pancreatic cancer cell lines. Figure S2. Oncomine analysis on differential expression of FOXL1 in multiple publicly available microarray datasets of pancreatic cancer. Figure S3. The effect of silencing FOXL1 by siRNA on cell growth, apoptosis and invasion in pancreatic cancer cells. Figure S4. The regulation of apoptosis-related gene expression by overexpression of FOXL1 in Panc1 cells.

  • Open Access

    Classification of drug use patterns

    by Christiaan H. Righolt, Geng Zhang, Salaheddin M. Mahmud

    Characterizing long‐term prescription data is challenging due to the time‐varying nature of drug use. Conventional approaches summarize time‐varying data into categorical variables based on simple measures, such as cumulative dose, while ignoring patterns of use. The loss of information can lead to misclassification and biased estimates of the exposure‐outcome association. We introduce a classification method to characterize longitudinal prescription data with an unsupervised machine learning algorithm. We used administrative databases covering virtually all 1.3 million residents of Manitoba and explicitly designed features to describe the average dose, proportion of days covered (PDC), dose change, and dose variability, and clustered the resulting feature space using K‐means clustering. We applied this method to metformin use in diabetes patients. We identified 27,786 metformin users and showed that the feature distributions of their metformin use are stable for varying the lengths of follow‐up and that these distributions have clear interpretations. We found six distinct metformin user groups: patients with intermittent use, decreasing dose, increasing dose, high dose, and two medium dose groups (one with stable dose and one with highly variable use). Patients in the varying and decreasing dose groups had a higher chance of progression of diabetes than other patients. The method presented in this paper allows for characterization of drug use into distinct and clinically relevant groups in a way that cannot be obtained from merely classifying use by quantiles of overall use.


  • Open Access

    Cytoreductive Nephrectomy Combined With Sequential Targeted Therapy For Treating Multiple Bilateral Metastatic Renal Cell Carcinoma: A Case Report

    by Wanxiang Zheng, Ming Gao, Guangdong Hou, Di Wei, Jiarui Yuan, Meihong Chen, Xinlong Dun, Geng Zhang, Fuli Wang, Fei Liu, et al.

    Targeted therapy is the standard treatment for advanced renal cell carcinoma that has been used extensively in the past decade. Sequential targeted therapy is an available choice for patients who develop drug resistance. However, it is debatable whether mammalian target of rapamycin inhibitor or another tyrosine kinase inhibitor should be used for sequential therapy after first-line anti-angiogenic drug treatment. In this study, we summarized the case report of a 51-year-old patient with advanced bilateral renal cancer who underwent tumor reduction surgery and sequential targeted therapy. First-line sunitinib, second-line everolimus, and third-line axitinib were given to this patient as part of a sequential therapy. The whole treatment process in details is described and discussed. The results indicate that cytoreductive nephrectomy combined with sequential targeted therapy is safe and effective in the treatment of multiple metastatic renal cell carcinoma. First-line sunitinib and subsequent axitinib may be a good choice for sequential therapy.